The D- Coded Directory

Decoded is the answer to a simple question – Why should one’s limited understanding of medical terminology, tech specs and research methodology come in the way of learning about their condition. Browse through our journal to get up to speed on all the latest and greatest in T1D research.

  • All Posts
  • Blog

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Biosimilar
MDI
Aspart

Understanding the article: “Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients”

Cardiovascular disease
LADA
RBC

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Biosimilar
MDI
Aspart

Understanding the article: “Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients”

Cardiovascular disease
LADA
RBC

Association between Continuous Glucose Monitoring metrics and clinical outcomes in adults with Type 1 Diabetes in a real-world setting.

CGM
Glycemic metrics
TIR

GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?

GLP-1 receptor agonists
SGLT2 inhibitors
MAG1C

An unwelcome inheritance: childhood obesity after diabetes in pregnancy

BMI
Insulin Resistance
Obesity
Hyperglycemia

Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges

IPCs
Stem Cells
Cell Therapy
Type 1 diabetes (T1D)

Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo-controlled trial.

C-peptide
Baricitinib
JAK
Monoclonal Antibodies
Type 1 diabetes (T1D)

The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis

COVID 19
PRISMA
SARS-CoV2
CI
Diabetes
Type 1 diabetes (T1D)

Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes.

Vertex
Efficacy
Endogenous
Immunosuppressive therapy
Hepatic portal vein
SHEs

Understanding the article: “The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview”

Severe hypoglycemia
Myocardial infarction
Retinopathy
Cardiovascular disease (CVD)
Diabetes
Type 1 diabetes (T1D)

Continuous Glucose Monitoring in pregnant women with type 1 diabetes CONCEPTT: a multicenter international randomized controlled trial.

CGM
Time in Range (TIR)
Intensive Insulin therapy
Glycemic Control
Pre-Eclampsia
Congenital Anomaly

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Trial Net
Clinical trial
Autoantibodies
Auto Immune system
Glucose tolerance test
Placebo
  • All Posts
  • Blog